Background. Metastatic recurrence after treatment for locoregional cancer is a major cause of morbidity and cancer-specific mortality. Distinguishing metastatic recurrence from the development of a second primary cancer has important prognostic and therapeutic value and represents a difficult clinical scenario. Advances beyond histopathological comparison are needed. We sought to interrogate the ability of comprehensive genomic profiling (CGP) to aid in distinguishing between these clinical scenarios. Materials and Methods. We identified three prospective cases of recurrent tumors in patients previously treated for localized cancers in which histologic analyses suggested subsequent development of a distinct second primary. Paired samples from the original primary and recurrent tumor were subjected to hybrid capture next-generation sequencingbased CGP to identify base pair substitutions, insertions, deletions, copy number alterations (CNA), and chromosomal rearrangements. Genomic profiles between paired samples were compared using previously established statistical clonality assessment software to gauge relatedness beyond global CGP similarities. Results. A high degree of similarity was observed among genomic profiles from morphologically distinct primary and recurrent tumors. Genomic information suggested reclassification as recurrent metastatic disease, and patients received therapy for metastatic disease based on the molecular determination.
INTRODUCTION
Despite advances in the management of localized cancers, recurrence remains a major cause of morbidity and cancerspecific mortality. Recurrence risk after primary therapy varies by cancer type and stage and is biologically attributed to micrometastases that escape detection at the time of initial therapy [1] . However, clinicians must consider the possibility of a second, distinct primary malignant process when evaluating potential recurrences, as patients are at risk for a second malignancy due to the same exposures and hereditary traits that contributed to development of their initial cancer and as a consequence of prior antineoplastic treatment [2] [3] [4] [5] .
Distinguishing between a metastatic recurrence of the original cancer and the development of a second primary tumor has important prognostic and therapeutic value. Clinical Cancer Diagnostics and Molecular Pathology context is important, but this distinction is primarily based on histopathologic comparison between tissue specimens. Unfortunately, this approach has limitations, including interobserver variability, tumor heterogeneity, and the fact that metastatic foci may have a distinct morphology due to tumor microenvironment influences or as a result of the very genomic alterations that led to recurrence and spread [6] [7] [8] .
Comprehensive genomic profiling (CGP) technologies may aid histopathologic analysis while simultaneously identifying therapeutically relevant genomic alterations [9] . This approach has been explored in patients with separate lung nodules to distinguish intrapulmonary metastasis from a separate, potentially curable, synchronous primary lung cancer [10, 11] . Anecdotal evidence from other tumor types in which nextgeneration sequencing aided pathologic interpretation has been reported, but variability in approach may limit generalizability [12] [13] [14] .
Here, we describe three cases of recurrent tumors in patients with prior, definitively treated, localized disease in which histopathologic analyses suggested development of a morphologically distinct second primary malignancy, but the addition of CGP strongly argued for a metastatic recurrence.
SUBJECTS, MATERIALS, AND METHODS

Case 1
A 60-year-old male smoker presented with an incidental lung lesion confirmed on positron emission tomography-computed tomography (PET-CT) as a 2.9 3 1.8-cm PET-avid right upper lobe (RUL) mass with no evidence of distant disease. Biopsy revealed non-small cell lung cancer (NSCLC). Following a negative mediastinoscopy, a right upper lobectomy was performed, and histopathologic analysis confirmed a 2.5-cm (pT2apN0M0) overall stage IB moderately differentiated adenocarcinoma with visceral pleural involvement ( Fig. 1A, 1B ). Immunohistochemical analysis demonstrated tumor cells staining positive for CK7 and napsin-A and negative for TTF-1, CK5/6, and p40. The patient did not receive adjuvant therapy and two months after surgery noted a left flank mass that was treated with local excision, revealing a morphologically distinct poorly differentiated non-small cell carcinoma (Fig. 1C, 1D ). Restaging PET-CT identified an additional right gluteal mass, and biopsy was histologically similar to the left flank mass. Histologic comparison was notable for prominent glandular elements and abundant mucin production in the resected NSCLC ( Fig. 1A ) but morphologically distinct epithelioid-like sheets of tumor cells with focal nest and cords, abundant eosinophilic to clear cytoplasm, large nuclei, and prominent nucleoli in the flank mass ( Fig. 1C ). There were no glandular elements and no mucin production in the flank mass. Additional immunohistochemical evaluation of the left flank mass showed tumor cells positive for CK7, CK5/6 (focal), AE1/AE3, CK903, CEA, thrombomodulin, CAIX, GATA-3 (nuclear), MAGE (31, >90%), and mesothelin (21, >50%) and negative for napsin-A, TTF-1, p63, CK20, PAX-8, uroplakin, melan A, HMB45, and NY-ESO. The degree of morphologic and immunohistochemical differences favored a pathologic conclusion of a second primary carcinoma of unknown origin over recurrent NSCLC. To investigate the possibility of the left flank mass representing an early NSCLC recurrence, both the RUL resection and left flank mass were subjected to a CGP assay as previously described [15] . The genomic signature of the two tumors showed significant overlap, with both specimens harboring an oncogenic KRAS Q61L mutation (Table 1 ). Based on the CGP results, the diagnosis was revised to recurrent, metastatic KRAS-mutant NSCLC and the patient received carboplatin plus pemetrexed for advanced NSCLC.
Case 2
A 68-year-old female presented with left-sided abdominal pain, and a CT scan identified a 15.3 3 11.3-cm left perirenal mass and three hepatic hypodensities radiographically consistent with benign cysts. She underwent a left radical nephrectomy, and histology was consistent with non-metastatic stage IV (pT3pN1M0) adrenocortical carcinoma (ACC) ( Fig. 2A ). The ACC was composed of nests of cells with moderate atypia, abundant eosinophilic cytoplasm, and areas of necrosis and hemorrhage. The adrenal tumor immunohistochemistry (IHC) was positive for inhibin, vimentin, MART-1, and CAM5.2 (focal) and negative for CK7, CK20, PAX-2, PAX-8, pankeratin, hepatocyte, and chromogranin. A CT scan 2.5 months post-resection demonstrated new liver lesions, and a CT-guided core biopsy revealed highgrade neuroendocrine carcinoma, histologically distinct from the resected ACC specimen (Fig. 2B ). The liver tumor was composed of numerous monomorphic epithelial cells arranged in cords and trabeculae with a high Ki67 proliferation index. The liver lesion stained positive for CAM5.2, CD56, and synaptophysin (focally) and negative for inhibin, MART-1, CK5/6, PAX-8, pankeratin, chromogranin, CDX2, and TTF-1. The original adrenal tumor was not stained for synaptophysin or CD56, and, as tissue was exhausted for DNA extraction for CGP, it was not able to be stained retrospectively. She was therefore diagnosed with a second primary neuroendocrine tumor. Genomic analyses performed on the resected ACC and the neuroendocrine liver biopsy confirmed both lesions shared multiple genomic alterations, strongly suggesting clonogenic spread and a unifying diagnosis ( Table 2 ). The patient was treated with cisplatin and etoposide based on activity in ACC and high-grade neuroendocrine tumors but was refractory to treatment and expired after 4 months of palliative chemotherapy.
Case 3
A 48-year-old female never-smoker was diagnosed with stage IIIC endometrioid-type endometrial adenocarcinoma (Fig. 3A,  3B ). She was treated with optimal cytoreduction and adjuvant carboplatin and paclitaxel followed by surveillance. One year after diagnosis, she was found to have an incidental enlarged right hilar lymph node on surveillance imaging, and bronchoscopic biopsy revealed an atypical carcinoma positive for pancytokeratin, chromogranin, and synaptophysin and negative for estrogen receptor, consistent with high-grade neuroendocrine/ small cell carcinoma and histologically divergent from her estrogen receptor-positive endometrioid primary ( Fig. 3C-3E ). Additional retrospective IHC stains confirmed the endometrial cancer was negative for synaptophysin, chromogranin, and CD56. In order to further evaluate a possible atypical ovarian recurrence, both the nodal biopsy and original surgical 
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Abbreviations: ND, none detected. specimen were subjected to CGP. Comparison between the genomic profiles showed nearly identical genomic alterations, more consistent with a metastatic recurrence than a second primary high-grade neuroendocrine/small cell carcinoma of the lung (Table 3 ). She is currently receiving therapy for advanced endometrial cancer and remains clinically well.
CGP
DNA was extracted and adaptor ligated sequencing libraries were captured by solution hybridization using custom bait-sets targeting 315 cancer-related genes and 28 frequently rearranged genes by DNA-seq (FoundationOne, Foundation Medicine, Cambridge, MA). All captured libraries were sequenced to high depth (Illumina HiSeq) in a Clinical Laboratory Improvement Amendments (CLIA)-certified College of American Pathologists (CAP)-accredited laboratory (Foundation Medicine), averaging >500x for DNA. Sequence data from genomic DNA and cDNA were mapped to the reference human genome (hg19) and analyzed through a computational analysis pipeline to call genomic alterations present in the sample, including substitutions, short insertions and deletions, rearrangements, and copy number variants, as previously described [15] .
Statistical Clonality Assessment
To estimate the statistical probabilities that the paired samples from our cases represented clonally related tumors, we utilized a previously reported method to infer clonality from next-generation sequencing (NGS)-derived copy number profiles [16, 17] . Briefly, this approach predicts clonal relation based on the number of shared/different loci that are amplified or lost between two samples. Using the statistical methods described by Ostrovnaya et al. (supplemental data), we observed strongest support for clonality in cases 1 and 3 [17] .
RESULTS
The shared and differing genomic alterations from our paired case samples are presented in Tables 1-3 . Copy number-based clonality testing strongly favored a shared origin in cases 1 and 3. When analyzed using a methodology incorporating somatic variants (data not shown), case 2 is highly suggestive of clonal relation [16] . Case 2 contained the greatest differences in CNA despite a high degree of shared short variants, and CNA-based analysis alone was less conclusive.
DISCUSSION
Here, we describe cases in which genomic alterations identified using CGP provide biologic rationale for reclassifying histopathologically and chronologically divergent samples (separate primaries) into metastatic disease, altering both prognosis and treatment approach. The increasing clinical use of molecular profiling may refine cancer taxonomy from a morphologic classification to a genomic one, providing information on tumor biology and potential pathways of drug treatment and resistance and increasing treatment individualization [18] . Previous studies have suggested a clinical utility of CGP in distinguishing metastatic NSCLC from synchronous primaries and in examining genetic alterations between primary breast and colorectal cancer and corresponding metastatic tumors [10, 11, [19] [20] [21] . Our cases lend further evidence to this approach.
Although we cannot definitively conclude a shared clonal origin using CGP, our cases offer several suggestive observations. The KRAS Q61L substitution seen in both samples from case 1 is a known oncogenic driver mutation strongly associated with NSCLC [22] . Prior series comparing primary tumor and synchronous metastases in NSCLC have shown very high concordance between driver alterations, a phenomenon observed across multiple malignancies [23] . Although large and rigorous statistical analyses are lacking, we would offer the following observation in support of shared origin in case 1. In The Cancer Genome Atlas characterization of NSCLC adenocarcinomas, KRAS Q61L exists in 0.4% of samples; thus, the expected probability of this alteration arising in a second independent primary NSCLC would be only 0.004 [24] . In addition, identical alterations in STK11, INHBA, KEAP1, and others were noted in both specimens, consistent with a shared genetic lineage (Table  1) . Somatic alterations in STK11 are seen in about one third of lung adenocarcinomas, and STK11 encodes the LKB1 protein, which inhibits angiogenesis; loss-of-function mutations promote cell growth and metastasis [25, 26] . Similarly, INHBA/Activin upregulation has been shown to promote metastasis in NSCLC [27] . In the absence of intervening therapy, the acquired (likely passenger) mutations in CDKN2A, ASXL1, and SMARCA4 may reflect clonal evolution in the time between RUL and left flank sampling. The concordance of recurrent somatic Table 3 . Comparison of genomic alterations between endometrioid-type endometrial adenocarcinoma and the histopathologicaly divergent nodal biopsy in case 3
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V920L ND alterations between primary and metastatic lesion separated in time is high and most well described for NSCLC and colorectal cancer; however, acquisition of passenger mutations (flank mass versus lung mass) reflecting genomic instability during the evolving metastatic process is expected [23, 28] . The genomic alterations in case 2 suggest similar biologic origins, with the additional alterations observed in the liver biopsy possibly reflecting a more aggressive and metastatic phenotype (Table 2) . Shared mutations were seen in the genes CTNNB1, TP53, and MLL2. The common alteration in b-catenin (CTNNB1) has been associated with the formation of large, nonsecreting, benign adrenal adenomas as well as ACCs, supporting the original histologic classification [29] . Genomic analysis from case 3 similarly supports the use of CGP. The ovarian primary harbors a common hotspot PIK3CA and b-catenin mutation, both seen frequently in endometrioid-type endometrial cancer ( Table 3 ) [30] . Conversely, the nodal biopsy with a small-cell histologic appearance lacks alterations in TP53 and RB1, which are seen in the majority (75%-90%) of small cell lung cancer [31, 32] . Taken together, comparative genomic analyses strongly argue for a shared clonal origin in all of our cases, and therapy was tailored to metastatic disease.
Although larger than prior single case studies, the major limitation of our series is the small sample size. The important question of the degree of genomic similarity required to conclude a shared biologic origin with high statistical confidence has not been comprehensively determined. Prior approaches, including differential X-chromosome inactivation status (female only), TP53 mutation status, comparative genomic hybridization (CGH), partial allelotyping, and microsatellite instability, have been used across several tumor types to assess clonality [11, [33] [34] [35] [36] . Without paired normal samples, our methodology cannot rule out the possibility that some of the shared alterations represent germline single nucleotide polymorphisms (SNPs). However, our CGP methodology (supplemental online data), coupled with the probability that separate nonclonogenic tumors sharing multiple identical alterations across a panel of over 300 genes would be exceedingly low, suggests our samples represent true metastatic recurrences. The reported variants of unknown significance are predicted to be somatic based on prior computational methods [37] . The case 3 SPOP E50K alteration exists in 3/240 (1.25%) of endometrioid-type endometrial cancer, suggesting a 1.25% chance of a second primary endometrial tumor sharing this alteration (assuming the first tumor has it) [30] . Furthermore, the ARID1A position 1088 alteration in case 3 is not a described germline single nucleotide variant in the single nucleotide polymorphism database (dbSNP) or National Heart, Lung, and Blood Institute Exome Variant Server, suggesting this is a true shared somatic alteration supporting a shared origin. Although not rigorously studied, the chance of two evolutionarily unrelated primary cancers (e.g., endometrial and small cell lung cancer) sharing one or more low-frequency somatic alterations has been reported to be extremely low [38] .
We attempted to incorporate prior clonality methods to support our observations. Copy number-based approaches strongly paralleled our comparative CGP conclusions for cases 1 and 3. The lower degree of support for case 2 may be exaggerated by the lack of incorporating somatic alterations in a CNA-based approach. Using another published method incorporating somatic changes, case 2 strongly favored clonal relationships. We recognize that without paired we cannot be 100% sure that some of our shared predicted somatic variants are not true germline variants not described in dbSNP database. However, we feel the shared CGP profiles and clinical timeline favor a clonal relationship in case 2.
Further support for our observation can be found in the converse clinical situation in which histopathologic similarities concluded an intrapulmonary metastasis (clonally related) but genomics suggested distinct separate primaries. In a series of 20 NSCLC patients with multiple lung tumors analyzed by array CGH and mass spectrometry based genotyping across 9 genes, the authors suggest clinicopathologic misclassification in up to 32% of cases [21] . NGS-based mate-pair (MP) analysis has also demonstrated utility in reclassifying cases in which histologic determination concluded a shared lineage [11] . The specific CGP assay used in our series (FoundationOne) has already been used in larger series to aid in separating histologically similar specimens into genomic subgroups [39] . To optimize clinical applicability, larger series across tumor types are needed to develop precise criteria for calling lineage determination. Similarly, our series raises, but does not answer, the balance between performing adequate IHC and preserving tissue for future or adjunct molecular studies. We expect that clinical development of larger gene panels, whole exome sequencing, and whole genome sequencing will allow for similar studies with even higher levels of confidence in assessing clonality. Importantly, CGP approaches have the added advantage of simultaneously identifying therapeutically relevant genomic alterations to guide treatment options, something not available with MP analysis, for example.
CONCLUSION
Our series highlights the diagnostic and therapeutic challenges of establishing a clonal link between a metastatic tumor and its primary lesion and supports further investigation into the use of CGP for lineage assessment between primary and metastatic lesions across tumor histologies. Larger series and clinic outcomes data will be important to refine the routine applicability, but our data support considerations for incorporating comparative CGP in patients for whom distinguishing metastatic recurrence from a second primary would alter the therapeutic approach.
